The results serve as motivation to incorporate accelerometer-derived outcomes in clinical trials, which is essential for further validation of these markers to meaningful endpoints.

van Eijk et al. report that oral trimetazidine is safe and well-tolerated in amyotrophic lateral sclerosis (ALS) patients, significantly reducing oxidative

There is a long history of ALS therapies being promoted on the basis of Phase 2 data, which then fail to translate into meaningful benefits in Phase 3 tria